Aromatase inhibition in advanced prostatic cancer: preliminary communication.

We report the results of the first use of a steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the palliation of patients with advanced, hormone resistant, prostatic cancer. Twelve of 19 patients (63%), who had relapsed following castration and other therapies, gained sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Shearer, R. J., Davies, J. H., Dowsett, M., Malone, P. R., Hedley, A., Cunningham, D., Coombes, R. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971817/
https://www.ncbi.nlm.nih.gov/pubmed/2201397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971817/
https://www.ncbi.nlm.nih.gov/pubmed/2201397

Ejemplares similares